Gensight Biologics : Resumption of CAA planned for December - Financing required in the short term
>Refinancing under negotiation - Gensight has announced a cash position of € 3.4m at the end of September (compared with € 6.9m at the end of June 2024), giving it financial visibility until mid-November 2024. The resumption of sales of Lumevoq through the compassionate access authorisation (CAA) programme in France is now scheduled for December, compared with November previously. The company is therefore in the process of negotiating ‘bridge financing’ for a ‘small ...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.